Cargando…

Advancements in bacteriophage therapies and delivery for bacterial infection

Having co-evolved with bacteria over hundreds of millions of years, bacteriophage are effective killers of specific bacterial hosts. Therefore, phage therapies for infection are a promising treatment avenue, can provide a solution for antibiotic resistant bacterial infections, and have specified tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Durr, Hannah A., Leipzig, Nic D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: RSC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987412/
https://www.ncbi.nlm.nih.gov/pubmed/36895585
http://dx.doi.org/10.1039/d2ma00980c
_version_ 1784901380472832000
author Durr, Hannah A.
Leipzig, Nic D.
author_facet Durr, Hannah A.
Leipzig, Nic D.
author_sort Durr, Hannah A.
collection PubMed
description Having co-evolved with bacteria over hundreds of millions of years, bacteriophage are effective killers of specific bacterial hosts. Therefore, phage therapies for infection are a promising treatment avenue, can provide a solution for antibiotic resistant bacterial infections, and have specified targeting of infectious bacteria while allowing the natural microbiome to survive which systemic antibiotics often wipe out. Many phages have well studied genomes that can be modified to change target, widen target range, or change mode of action of killing bacterial hosts. Phage delivery can also be designed to increase efficacy of treatment, including encapsulation and delivery via biopolymers. Increased research into phage potential for therapies can allow new avenues to develop to treat a larger range of infections.
format Online
Article
Text
id pubmed-9987412
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher RSC
record_format MEDLINE/PubMed
spelling pubmed-99874122023-03-07 Advancements in bacteriophage therapies and delivery for bacterial infection Durr, Hannah A. Leipzig, Nic D. Mater Adv Chemistry Having co-evolved with bacteria over hundreds of millions of years, bacteriophage are effective killers of specific bacterial hosts. Therefore, phage therapies for infection are a promising treatment avenue, can provide a solution for antibiotic resistant bacterial infections, and have specified targeting of infectious bacteria while allowing the natural microbiome to survive which systemic antibiotics often wipe out. Many phages have well studied genomes that can be modified to change target, widen target range, or change mode of action of killing bacterial hosts. Phage delivery can also be designed to increase efficacy of treatment, including encapsulation and delivery via biopolymers. Increased research into phage potential for therapies can allow new avenues to develop to treat a larger range of infections. RSC 2023-01-31 /pmc/articles/PMC9987412/ /pubmed/36895585 http://dx.doi.org/10.1039/d2ma00980c Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Durr, Hannah A.
Leipzig, Nic D.
Advancements in bacteriophage therapies and delivery for bacterial infection
title Advancements in bacteriophage therapies and delivery for bacterial infection
title_full Advancements in bacteriophage therapies and delivery for bacterial infection
title_fullStr Advancements in bacteriophage therapies and delivery for bacterial infection
title_full_unstemmed Advancements in bacteriophage therapies and delivery for bacterial infection
title_short Advancements in bacteriophage therapies and delivery for bacterial infection
title_sort advancements in bacteriophage therapies and delivery for bacterial infection
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987412/
https://www.ncbi.nlm.nih.gov/pubmed/36895585
http://dx.doi.org/10.1039/d2ma00980c
work_keys_str_mv AT durrhannaha advancementsinbacteriophagetherapiesanddeliveryforbacterialinfection
AT leipzignicd advancementsinbacteriophagetherapiesanddeliveryforbacterialinfection